
Around 1 in 5 people diagnosed with cancer in the UK take part in a clinical trial.
This trial looked at imiquimod cream to treat an early type of melanoma skin cancer called lentigo maligna.
The higher the supposed cure rate of imiquimod cream the more people said it would be their first choice of treatment.
Half the people said they would choose surgery over imiquimod cream even when the cure rate of imiquimod cream was 85 out of every 100 people (85%).
Conclusion
The trial team concluded that imiquimod cream didn’t work well enough to do a larger phase 3 trial to compare it with surgery.
Where we got this information from
We have based this summary on information from the research team. The information they sent us has been reviewed by independent specialists () and published in a medical journal. The figures we quote above were provided by the trial team who did the research. We have not analysed the data ourselves.
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Dr Jerry Marsden
NIHR Research for Patient Benefit (RfPB) Programme
NIHR Clinical Research Network: Cancer
University Hospital Birmingham NHS Foundation Trust
Freephone 0808 800 4040
Around 1 in 5 people diagnosed with cancer in the UK take part in a clinical trial.